Public health, health services research and health economics THU0599 BENEFIT RISK RATIO FOR BIOLOGICAL AGENTS IN JUVENILE IDIOPATHIC ARTHRITIS, A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
Background: The biological agents (BAs) have revolutionized the care and have improved the prognosis of juvenile idiopathic arthritis (JIA). Effectiveness and short-term tolerance was well established in randomized clinical trials (RCTs), initially in JIA. However, there is an insufficient evidence for the long-term tolerance 1 . The serious adverse events (SAEs) include infections, malignancies and drug induced auto-immune diseases (e.g. uveitis). Objectives: To assess the benefit/risk balance of BAs assessed by RCTs vs placebo or vs standard treatment in JIA, using meta-analysis (MA) technique. Methods: All RCTs in JIA comparing BAs to placebo or standard treatment (e.g. methotrexate) published between 1950 and February 2016 were eligible. Data source: Cochrane, Medline, ClinicalTrial.gov register. The ILAR classification for JIA 2 was used and the clinical efficacy of treatment was measured by the ACR pediatric score 3 . Efficacy was analyzed considering the design of study. Effectiveness (ACRpedi30) was estimated as the measure of the benefit of the BAs and SAEs as a measure of risk by random effect models. The benefit/risk balance was analyzed using the net efficacy adjusted for risk (NEAR) 4 . An OR >1 indicates that the treatment has a beneficial effect and OR <1 a deleterious effect. Subgroups analyses were made to account the heterogeneity of JIA. We explored potential heterogeneity by subgroups analysis according with BAs and JIA subtypes. Results: We included 20 RCTs conducted in JIA encompassing 1533 children. The disease duration, at the inclusion of RCTs, varies between 2 and 6 years for most studies. The maintenance of the therapeutic effect was estimated in the studies using withdrawal design in 6 studies. The maintenance of clinical response showed a large heterogeneity. Sub-groups analyses showed that the heterogeneity is marked in the systemic JIA 5 . The global NEAR OR was in favor of BAs in parallel (OR 3.83, Background: Adverse childhood experiences (ACE) such as abuse, neglect and household challenges are associated with poorer adult health status and onset of rheumatic diseases. There has been no research associating ACE with outcomes among adults with systemic lupus erythematosus (SLE). Objectives: To characterize relationships of ACE and health outcomes of disease activity, damage, quality of life and depression in SLE patients. Methods: Data were derived from the California Lupus Epidemiology Study (CLUES), a population based, multi-ethnic cohort of patients with SLE. Participants completed self-report measures of SLE activity (Systemic Lupus Activity Questionnaire; SLAQ), damage (Brief Index of Lupus Damage; BILD), quality of life (SF-36), depression (Patient Health Questionnaire; PHQ8) and sociodemographics. They completed the Adverse Childhood Experiences (ACE) survey, a validated 10-item scale covering 3 domains (abuse, neglect and household challenges prior to age 18). We compared demographics and SLE outcomes by ACE score and domains using ANOVA. Results: The 166 CLUES participants were mostly women (89%) and were racially/ethnically diverse (31% non-Hispanic White, 22% Hispanic, 15% African American, 31% Asian American). Mean age was 44±14; mean age at diagnosis 28±12. The median ACE score was 1; 30 (18%) had a score of 4 or higher. ACE scores ≥4 were more common in Hispanic (27%) and African American (32%) participants (p=0.01) compared to other races/ethnic groups, and in participants with poverty level incomes (61% vs 13%, p<0.001); but did not differ by education or age at study entry or diagnosis. Higher overall ACE scores were associated with greater SLE activity and damage, poorer quality of life, and higher levels of depressive symptoms. For each ACE domain, increasing scores were generally associated with worse outcomes, but did not always reach statistical significance (Table) . 
